Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has reported a significant stock transaction by a top executive in a recent filing. Chief Business Officer Gad Thomas sold a total of 32,351 shares of the company's common stock, fetching a total of $395,563. The transactions occurred on two separate dates, with shares sold at prices ranging from $12.00 to $13.00.
On May 21, 2024, Thomas sold 25,000 shares at a price of $12.00 per share. Following this transaction, he executed another sale on May 23, 2024, disposing of 7,351 shares. This latter sale was carried out in multiple trades with prices ranging from $13.00 to $13.01, with the reported price reflecting the weighted average sale price. The sales were conducted indirectly through GAD Enterprises LLC, an entity in which Thomas holds sole voting and dispositive power.
The recent filings indicate that, despite these sales, Thomas still maintains a substantial stake in Y-mAbs Therapeutics. Post-transaction, he has an indirect ownership of 240,032 shares through GAD Enterprises LLC and direct ownership of 158,700 shares. Additionally, 60,000 shares are owned by his children, who share his household, bringing his total reported affiliated ownership to 458,732 shares following the transactions.
Investors often monitor insider transactions as they can provide insights into executives' perspectives on the company's current valuation and future prospects. The sales by Thomas come at a time when the market is keenly observing the moves of company insiders.
For further details on the transactions, including the specific number of shares sold at each price point, Y-mAbs Therapeutics has stated that full information is available upon request to the Securities and Exchange Commission (SEC), the issuer, or a security holder of the issuer.
InvestingPro Insights
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been navigating a complex market landscape, as reflected in the recent stock transactions by Chief Business Officer Gad Thomas. To provide investors with a broader context, here are some key metrics and insights from InvestingPro. With a market capitalization of $544.14 million, Y-mAbs Therapeutics is a mid-sized player in the biotechnology sector. Despite a challenging market environment, the company boasts a robust gross profit margin of 86.41% over the last twelve months as of Q1 2024. This underscores the company's ability to maintain high profitability in relation to sales, which is a positive indicator for investors.
An InvestingPro Tip to consider is the company's strong liquidity position, as Y-mAbs holds more cash than debt on its balance sheet. This financial health metric is crucial for investors, especially when assessing the company's ability to sustain operations and invest in growth opportunities. Additionally, the company's liquid assets exceed its short-term obligations, which further attests to its financial resilience.
On the flip side, the company's P/E ratio stands at -25.08, reflecting market skepticism about its earnings potential in the near term. Analysts do not anticipate Y-mAbs will be profitable this year, which is a critical consideration for investors. Moreover, the stock has experienced a significant price uptick over the last six months with a total return of 127.52%, yet it has fared poorly over the last month with a -19.17% return. This volatility highlights the importance of keeping an eye on market trends and company performance.
To access more detailed analysis and additional InvestingPro Tips for Y-mAbs Therapeutics, visit InvestingPro. Currently, there are 9 additional tips available, offering comprehensive insights for investors. Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.